Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT02059278 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

335

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: T-2345
DRUG: Xalatan

Sponsor

Nephron Pharmaceuticals Corporation